Initial Predictors for Short-Term Prognosis in Anti-Melanoma Differentiation-Associated Protein-5 Positive Patients

Qihua Yang (fccyangqh@zzu.edu.cn)  
Zhengzhou University First Affiliated Hospital  
https://orcid.org/0000-0001-7183-3366

Tianfang Li  
Zhengzhou University First Affiliated Hospital

Xin Zhang  
Zhengzhou University First Affiliated Hospital

Kunlong Lyu  
Zhengzhou University First Affiliated Hospital

Shujun Wu  
Zhengzhou University First Affiliated Hospital

Yan Chen  
Zhengzhou University First Affiliated Hospital

Shengyun Liu  
Zhengzhou University First Affiliated Hospital

Zujiang Yu  
Zhengzhou University First Affiliated Hospital

Research

Keywords: anti-melanoma differentiation-associated protein-5, interstitial lung disease, clinically amyopathic dermatomyositis, dermatomyositis

DOI: https://doi.org/10.21203/rs.3.rs-40977/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Anti-melanoma differentiation-associated protein-5 (anti-MDA5) positive patients are characterized by the high mortality rate caused by interstitial lung disease (ILD). We conducted a retrospective study to summarize the clinical features and identify the initial predictors for death in anti-MDA5 positive patients.

**Methods:** We designed a retrospective cohort of anti-MDA5 positive patients. The demographic and clinical data recorded on first admission, as well as the outcomes during the first six months follow-up, were collected. Predictors of rapidly progressive ILD (RPILD) and poor outcomes were calculated using logistic regression models and Cox proportional hazard regression models, respectively.

**Results:** A total of 90 anti-MDA5 positive patients were included in this study. Eighty-one (90%) patients presented ILD on admission and 35 (38.9%) patients developed RPILD subsequently. During the first six months of follow-up, 22 (24.4%) patients died of respiratory failure at an average time of 6.6 ± 5.9 weeks. Factors including disease duration < 2 months (OR 6.1, 95% CI 1.7-22.4, \( P = 0.007 \)), serum ferritin \( \geq 1500 \) ng/ml (OR 12.3, 95% CI 3.1-49.6, \( P < 0.001 \)), CRP \( \geq 13 \) mg/L (OR 4.6, 95% CI 1.3-16.9, \( P = 0.021 \)) and total GGO score \( \geq 4 \) (OR 6.3, 95% CI 1.8-21.9, \( P = 0.003 \)), were identified as independent predictors for RPILD. Cox regression model showed that total CT GGO score \( \geq 4 \) (HR 4.8, 95% CI 1.3-17.9, \( P = 0.020 \)), KL-6 > 1600 U/ml (HR 3.7, 95% CI 1.5-9.1, \( P = 0.004 \)) and CRP > 5.8 mg/L (HR 3.7, 95% CI 1.0-12.8, \( P = 0.044 \)) were poor prognostic risk factors, however initial combined treatment (HR 0.3, 95% CI 0.1-0.8, \( P = 0.019 \)) predicted good prognosis in anti-MDA5 positive patients.

**Conclusion:** Anti-MDA5 positive patients demonstrated a high prevalence of ILD on admission, leading to a high short-term mortality rate. Higher total GGO score, higher levels of initial KL-6 and CRP predict poor outcome in anti-MDA5 positive patients. However, initial intensive treatment may improve the prognosis.

**Background**

In 2005, anti-melanoma differentiation-associated protein-5 (anti-MDA5) was identified as a novel autoantibody by Sato [1], in patients diagnosed of clinically amyopathic dermatomyositis (CADM), which was defined as having a manifestation of typical skin lesions of dermatomyositis (DM) without clear evidence of myopathy. Since then, a lot of studies have verified the association between anti-MDA5 and CADM [2, 3]. Accumulating evidences have demonstrated that patients with anti-MDA5 often have a high mortality rate caused by rapidly progressive interstitial lung disease (RPILD) [2–6]. While immunosuppressive treatment has improved the outcome of anti-MDA5 positive patients [7, 8], there still were patients failing to respond and dying of respiratory failure shortly after the diagnosis was established.

Risk factors predicting poor prognosis have been established in polymyositis (PM)/DM patients including age, serum ferritin level, skin ulcers, peripheral capillary oxygen saturation (\( \text{PaO}_2 \)) and anti-MDA5 antibody [2, 9–11], among which anti-MDA5 antibody was consistently reported as poor prognostic risk
factor in most studies [12]. Of note, in the study containing all types of myositis, anti-MDA5 has such a strong association with poor prognosis, that it dominates the analysis and makes other potential poor prognostic factors even tend to be a protective factor [11]. While in the subgroup of anti-MDA5 positive patients, the reported risk factors varied in different reports, possibly due to small sample size [5, 9, 13].

Therefore, we conducted a retrospective cohort of 90 anti-MDA5 positive patients, which involved in different departments including rheumatology, pneumonology and dermatology. This study was designed to summarize the clinic-biological characteristics and identify the prognostic factors in anti-MDA5 positive patients.

**Methods**

**Patients**

We conducted a retrospective study of patients who visited the First Affiliated Hospital of Zhengzhou University and were diagnosed with anti-MDA5 positive DM/CADM or PM for the first time, from September, 2018 to December, 2019. The exclusion criteria included: 1) age < 16 years old, 2) complicated with other connective tissue diseases, 3) complicated with lethal carcinoma that occurred before, 4) incomplete clinical or laboratory data necessary for this study. The diagnosis of classical DM and PM were based on Bohan and Peter criteria [14, 15], and CADM was based on Sontheimer criteria [16]. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2020-KY-194).

**Data collection**

A standard form was used to collect demographic, clinical and laboratory data from medical records. Data collection included the age of disease onset, gender, duration, and symptom. The laboratory data included the serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), Krebs von den Lungen-6 (KL-6), ferritin, ESR, CRP and the titer of ANA. All patients were tested for a panel of myositis-specific antibodies (MSAs) and myositis-associated antibodies (MAAs) including anti-MDA5 and TIF1-γ antibodies using ELISA kits (MBL, Japan), and anti-OJ, EJ, PL7, PL12, SRP, Jo-1, Mi-2, Ku and Ro52 antibodies using lining immunofluorescence (Euroimmun, Germany) by following the manufacturer’s instructions.

The initial treatment regimens were also recorded according to medical records, including glucocorticoid (GC), calcineurin inhibitors (CNI) such as tacrolimus and cyclosporine A, cyclophosphamide (CYC), and intravenous immunoglobulin (IVIG). High-dose GC is defined of a prednisolone equivalent of 1mg/kg daily. Initial combined treatment is defined as a combination of high dose GC and at least one immunosuppressant starting immediately after diagnosis. The main outcome was death. Survival status was respectively or prospectively confirmed by hospital records or the follow-up calls.

**HRCT findings**
All patients were subjected to high-resolution computed tomography (HRCT) scan on admission. After excluding infections, RPILD was defined as following: deteriorating dyspnea on exertion, decrease in PaO$_2$ levels by >10 mmHg within 4 weeks, or expanding GGO on HRCT within 4 weeks. HRCT findings were assessed both in GGO score and fibrosis score using the method proposed by Kazerooni et al. [17].

Every patient’s HRCT was evaluated in three limited levels: the mid-aortic arch, left tracheal bifurcation, and 1 cm above the diaphragm. Each lobe (right upper, middle, and lower, and left upper and lower lobes) was scored at the three sites on a scale of 0-5 as follows: GGO scores for GGO involving the lobe: 0, none; 1, $\leq$ 5%; 2, 5% to $<$ 25%; 3, 25% to 49%; 4, 50% to 75%; and 5, $>$ 75%. Similarly, fibrosis scores were assessed according to honeycombing involving the lobe: 0, none; 1, interlobular septal thickening without discrete honeycombing; 2, $<$ 25%; 3, 25-49%; 4, 50-75%; and 5, $>$ 75%. The images were independently reviewed by a pulmonary radiologist and a respiratory specialist (C. Y and W. SJ) blinded to the patients’ clinical information. Disagreement between two observers was solved by consensus. Total GGO scores and fibrosis scores were calculated by summing the scores of the five lobes.

**Statistical analysis**

Hypothesis testing was performed for comparing continuous variables in different outcome groups using $t$-test or Mann-Whitney U test. Categorical variables were assessed by the Chi-squared test or Fisher’s exact test.

All continuous variables were converted to dichotomous variables for univariate and multivariate analysis, and cut-off values were determined by receiver operating characteristics (ROC) [18]. Factors associated with RPILD were subjected to univariate logistic regression analysis. The predictive factors of RPILD with $P < 0.1$ in univariate analysis were included in a multiple logistic regression model. Variables were selected by a forward stepwise (likelihood ratio) procedure based on the $P$-value. Factors associated with poor outcome of anti-MDA5 positive patients were subjected to univariate analysis using the log rank test. Variables with $P < 0.1$ in the univariate analysis were sequentially included in the multivariate Cox regression analysis, and the forward stepwise (likelihood ratio) method was used to select the variables that were eventually included in the model. Kaplan-Meier analysis with the log-rank test was used for factors selected by final model for predictors for mortality.

Statistical analysis was performed using SPSS software (ver 20.0, USA) and MedCalc software (ver 18.2.1, Belgium). The significance levels were computed for 2-tailed testing and the cutoff of significance was set at $P < 0.05$.

**Results**

**Baseline features and outcomes of anti-MDA5 positive patients**
A total of 90 anti-MDA5 positive patients were included in our study. The demographic features, antibody variables and treatment regimens on admission, and the clinical outcomes were recorded in Table 1. The average age at disease onset was 51.9 ± 12.1 years, and female accounted for 63.3% of the cohort. This cohort consisted of 70 (77.8%) CADM, 19 (21.1%) DM and 1 (1.1%) PM cases, among whom the CADM patients accounted for the majority. All the patients were negative for other MSAs except anti-MDA5 antibody. Meanwhile, 64 (71.1%) patients were also positive for anti-Ro52 antibody, indicating the necessity to test MSAs in patients positive for anti-Ro52.

Although almost all patients were diagnosed in early stage at a median time of 3.7 months, 81 (90%) patients already presented ILD on admission and 35 (38.9%) patients developed RPILD subsequently. During the first six months follow-up, a high mortality rate of 24.4% was observed in our cohort. Patients all died of respiratory failure caused by ILD, some of whom were complicated with infections in the end stage, at an average time of 6.6 ± 5.9 weeks (range 1–24 weeks) after diagnosis.

During the first six months follow-up, malignancies were found in three CADM patients: one with esophageal cancer, one with lung adenocarcinoma and one with thyroid carcinoma. However, no patient died of malignancy in the first six months.

**Comparison Of Clinical Features Between Survivors And Non-survivors**

No significant difference was observed in other demographic features, except the non-survivors were significantly older at the age of disease onset than the survivors. As to the laboratory data, the death group presented a significant higher initial serum levels of ferritin, KL-6, LDH, ESR and CRP, suggesting a more intensive inflammation inside, than the survival group. The non-survivors had a significant higher incidence of anti-Ro52 positivity than the survivors, reminding physicians to pay attention to the patients who were double-positive for anti-MDA5 and anti-Ro52. Not surprisingly, the non-survivors had significant worse HRCT presentations on admission, both in total CT fibrosis score and total GGO score. Initial combination therapy was more common in the survivors, but the use of IVIG was of no significant difference between the two groups. (Table 1)

**Treatment Regimens**

All patients were treated with high-dose GC at diagnosis, of whom 58 cases were initially combined with CNI and/or CYC and 32 cases were step-up treated. In our cohort, CNI was a preferable choice than CYC but without significant difference (41.1% vs. 31.1%, \( P = 0.16 \)). Only seven patients (7.8%) were treated with a triple combination of high-dose GC with CYC and CNI, due to the concern of serious infections. Additional IVIG (0.4 g/kg daily) was administered in 43 cases based on physician's decision after comprehensive assessment of patients' condition. (Table 2)
Factors Associated With Rpild In Anti-mda5 Positive Patients

In univariate analysis, factors including age, fever, serum ferritin, CRP, KL-6, lymphocyte, anti-MDA5, total GGO score and total fibrosis score were found significantly associated with RPILD. In logistic multivariate analysis, disease duration < 2 months (OR 6.1, 95% CI 1.7–22.4, \( P = 0.007 \)), serum ferritin \( \geq 1500 \) ng/ml (OR 12.3, 95% CI 3.1–49.6, \( P < 0.001 \)), CRP \( \geq 13 \) mg/L (OR 4.6, 95% CI 1.3–16.9, \( P = 0.021 \)) and total GGO score \( \geq 4 \) (OR 6.3, 95% CI 1.8–21.9, \( P = 0.003 \)) were identified as independent risk factors for RPILD. (Table 3)

Factors associated with outcomes in anti-MDA5 positive patients

To identify the prognostic factors associated with death in anti-MDA5 positive patients, we performed univariate analysis using all the initial variables. In the univariate analysis, a number of variables, including demographic, clinical, laboratory and image parameters were found significantly related to death, while initial combination related to survival. In the multivariate Cox regression analysis, we identified total CT GGO score \( \geq 4 \) (HR 4.8, 95% CI 1.3–17.9, \( P = 0.020 \)), initial KL-6 > 1600 U/ml (HR 3.7, 95% CI 1.5–9.1, \( P = 0.004 \)), CRP > 5.8 mg/L (HR 3.7, 95% CI 1.0-12.8, \( P = 0.044 \)) as independent predictors for death, and initial combination (HR 0.3, 95% CI 0.1–0.8, \( P = 0.019 \)) as a predictor for survival. (Table 4).

To better understand prognostic value of the aforementioned risk factors, the survival curves of patients divided by the aforementioned risk factors using Kaplan-Meier analysis were shown in Fig. 1.
| Demographic features | Total patients (n = 90) | Survival group (n = 68) | Death group (n = 22) | P value |
|----------------------|------------------------|------------------------|---------------------|---------|
| Female, n (%)        | 57 (63.3)              | 43 (63.2)              | 14 (63.6)           | 0.973   |
| Age, yrs, mean ± SD  | 51.9 ± 12.1            | 49.5 ± 11.4            | 59.2 ± 11.6         | 0.001*  |
| Disease duration, months, median (IQR) | 2.0 (1.0, 3.8) | 2.0 (1.0, 4.0) | 1.0 (1.0, 2.8) | 0.086 |

| Clinical features | Total patients (n = 90) | Survival group (n = 68) | Death group (n = 22) | P value |
|-------------------|------------------------|------------------------|---------------------|---------|
| CADM, n (%)       | 70 (77.8)              | 51 (75.0)              | 19 (86.4)           | 0.380   |
| Raynaud's phenomenon, n (%) | 9 (10.0)   | 7 (10.3)              | 2 (9.1)             | 1.000   |
| Gottron's papules, n (%) | 61 (67.8)  | 46 (67.6)            | 15 (68.2)           | 1.000   |
| Skin ulcer, n (%) | 2 (2.2)                | 1 (1.5)                | 1 (4.5)             | 0.431   |

| Laboratory test | Total patients (n = 90) | Survival group (n = 68) | Death group (n = 22) | P value |
|-----------------|------------------------|------------------------|---------------------|---------|
| Serum ferritin, ng/ml, median (IQR) | 875.0 (538.2, 1794.2) | 734.5 (426.2, 1255.5) | 2198.5 (1008.8, 2923.5) | < 0.001* |
| KL-6, U/ml, median (IQR) | 939.5 (654.2, 1362.5) | 857.0 (640.8, 1202.2) | 1736.0 (830.0, 2958.5) | 0.002* |
| CK, U/L, median (IQR) | 64.5 (34.2, 122.5)    | 64.5 (34.0, 114.5)    | 72.5 (41.8, 132.2)   | 0.508   |
| CRP, mg/L, median (IQR) | 6.4 (2.8, 21.8)    | 4.4 (1.7, 16.5)     | 23.0 (11.2, 44.7)   | < 0.001* |
| ESR, mm/h, median (IQR) | 32.0 (22.0, 48.0)    | 30.5 (19.8, 45.0)    | 37.0 (27.2, 71.8)   | 0.043*  |
| Lymphocyte, x10^9/L, median (IQR) | 0.7 (0.6, 1.1)    | 0.8 (0.6, 1.2)     | 0.6 (0.4, 0.9)    | 0.014*  |
| Anti-Ro52, n (%) | 64 (71.1)            | 44 (64.7)            | 20 (90.9)           | 0.018*  |
| Anti-MDA5, U/ml, median (IQR) | 188.5 (158.5, 206.3) | 187.5 (155.5, 206.0) | 192.3 (165.8, 205.0) | 0.333   |
| ANA ≥ 1:320, n (%) | 15 (16.7)          | 11 (16.2)            | 4 (18.2)            | 1.000   |

CADM, clinically amyopathic dermatomyositis; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; anti-MDA5, anti-melanoma differentiation-associated protein-5; ANA, anti-nuclear antibody; HRCT, high-resolution CT; GGO, ground-glass opacity; CNI, calcineurin inhibitors; CYC, cyclophosphamide; IVIG, intravenous immunoglobulin; SD, standard deviation; IQR, interquartile range; * significant
| Variables (n = 90) | Value |
|-------------------|-------|
| **Initial combination therapy, n (%)** | 58 (64.4) |
| High dose GC + CNI, n (%) | 30 (30.0) |
| High dose GC + CYC, n (%) | 21 (23.3) |
| High dose GC + CNI + CYC, n (%) | 7 (7.8) |
| **Step-up therapy, n (%)** | 32 (35.6%) |
| **Additional treatment** | |
| IVIG, n (%) | 43 (47.8) |
| Hemodialysis | 2 (2.22) |

CADM, clinically amyopathic dermatomyositis; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; anti-MDA5, anti-melanoma differentiation-associated protein-5; ANA, anti-nuclear antibody; HRCT, high-resolution CT; GGO, ground-glass opacity; CNI, calcineurin inhibitors; CYC, cyclophosphamide; IVIG, intravenous immunoglobulin; SD, standard deviation; IQR, interquartile range; * significant
|                          | **Univariate analysis** |                     |                     | **Multivariate analysis** |                     |                     |
|--------------------------|-------------------------|---------------------|---------------------|--------------------------|---------------------|---------------------|
|                          | **OR** | **95% CI** | **P value** | **OR** | **95% CI** | **P value** |
| Age ≥ 55 yrs             | 5.5    | 2.2–14    | < 0.001*     | -      | -         | -           |
| Disease duration < 2 months | 4.3    | 1.7–10.7 | 0.002*     | 6.1    | 1.7–22.4  | 0.007*     |
| Serum ferritin ≥ 1500 ng/ml | 11.9   | 4–35.3   | < 0.001*    | 12.3   | 3.1–49.6  | < 0.001*   |
| KL-6 ≥ 1600 U/ml        | 6.3    | 2–19.9   | 0.002*     | -      | -         | -           |
| CRP ≥ 13 mg/L           | 5.3    | 2.1–13.5 | < 0.001*    | 4.6    | 1.3–16.9  | 0.021*     |
| Lymphocyte < 0.5 × 10^9/L | 3.3    | 1.2–9.1  | 0.024*     | -      | -         | -           |
| Anti-MDA5 ≥ 190 U/ml    | 2.4    | 1–5.7    | 0.051      | -      | -         | -           |
| Total CT GGO score ≥ 4  | 10.2   | 3.8–37.5 | < 0.001*    | 6.3    | 1.8–21.9  | 0.003*     |

KL-6, Krebs von den Lungen-6; CRP, C-reactive protein; anti-MDA5, anti-melanoma differentiation-associated protein-5; GGO, ground-glass opacity; * significant
Table 4
Initial parameters associated with death using a Cox regression model

|                      | Univariate analysis |                          |                          | Multivariate analysis |                          |                          |
|----------------------|---------------------|--------------------------|--------------------------|-----------------------|--------------------------|--------------------------|
|                      | HR                  | 95% CI                   | P value                  | HR                    | 95% CI                   | P value                  |
| Age ⩾ 55 yrs         | 5.0                 | 2.1–11.9                 | < 0.001*                 | -                     | -                        | -                        |
| Disease duration < 2 months | 2.1 | 0.9–5.2                 | 0.088                    | -                     | -                        | -                        |
| Lymphocyte < 0.6 × 10^9/L | 2.5 | 1.0–6.4                 | 0.047*                   | -                     | -                        | -                        |
| Serum ferritin ⩾ 2000 ng/ml | 14.9 | 5.2–42.6                | < 0.001*                 | -                     | -                        | -                        |
| KL-6 ⩾ 1600 U/ml     | 23.6                | 7.2–77.2                 | < 0.001*                 | 3.7                   | 1.5–9.1                  | 0.004*                   |
| CRP ⩾ 5.8 mg/L       | 5.1                 | 2.2–11.9                 | < 0.001*                 | 3.7                   | 1.0–12.8                 | 0.044*                   |
| ESR ⩾ 23 mm/h        | 3.6                 | 1.4–9.1                  | 0.006*                   | -                     | -                        | -                        |
| Anti-Ro52            | 2.9                 | 1.2–7.4                  | 0.021*                   | -                     | -                        | -                        |
| Total CT GGO score ⩾ 4 | 10.8 | 4.4–26.4                | < 0.001*                 | 4.8                   | 1.3–17.9                 | 0.020*                   |
| Total CT fibrosis score ⩾ 10 | 49.7 | 11.4–216.1              | < 0.001*                 | -                     | -                        | -                        |
| Initial combined treatment | 0.1 | 0.04–0.3                | < 0.001*                 | 0.3                   | 0.1–0.8                  | 0.019*                   |

KL-6, Krebs von den Lungen-6; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GGO, ground-glass opacity; * significant

Discussion

It has been reported that there are two waves of fatal events in PM/DM patients, and the first wave of mortality is caused by ILD and infections in the early stage [19]. Our study has revealed a high prevalence of ILD in anti-MDA5 positive patients, consistent with previous studies in Europeans and Japanese [2, 20]. The short-term mortality rate of anti-MDA5 positive patients was especially high within the first 6–12 months [5, 9, 13]. Based on these findings, we set to analyze the first six months living situation and identify the predictive factors for death in anti-MDA5 positive patients. Factors including shorter disease duration, higher total GGO score, higher levels of serum ferritin and CRP were found independently associated with RPILD. The multivariate analysis has confirmed that higher total GGO score, higher levels of initial KL-6 and CRP are poor prognostic factors, and that initial combined treatment predicts favorable outcome in anti-MDA5 positive patients.

It has been widely accepted that MSAs, especially anti-MDA5 antibody, have an important role in predicting prognosis of PM/DM patients. When the cohort contains patients with all types of myositis, the significance of anti-MDA5 antibody in predicting death is dominating, leading to other potential risk
factors ignored [11]. However, the predictive value may be reduced when MSAs were not completely examined in the cohort [21]. We would like to emphasize that every patient in our cohort was tested for a panel of important MSAs and MAAs, and that anti-MDA5 positive patients were recruited from different specialties to avoid a potential selection bias.

In the current study, both total GGO and total fibrosis score were significantly higher in the deceased group than the survival group. However, only total GGO score was identified as an independent predictor for RPILD and poor outcome in the multivariate analysis. This may be caused by the fact that honeycombing, an important component of fibrosis scoring, is less common in the early stage of anti-MDA5 associated ILD. On the contrary, GGO was a quite common pattern in the early stage. Similarly, in a prospective study, patients with GGO in all six lung fields at baseline all died of respiratory failure during follow-up [5]. Fujiki et al. [22] also reported the prognosis of patients with right middle lung lobe GGO score ≥ 2 was poor. Different from the wide consensus on the utility of CT score, the effect of initial KL-6 level was still controversial in different reports [9, 11, 13, 21–23]. In our cohort, we found the cut off value of initial KL-6 > 1600 U/ml as an independent poor prognostic predictor and the cumulative six-months survival rate differed significantly. In addition, Ye et al. [13] reported initial KL-6 of 792 U/ml as the cut-off for discriminating between survivors and non-survivors in anti-MDA5 positive patients. Moreover, dynamic change of KL-6 level, like marked increase of serum KL-6 during the first four weeks, has also been reported as a poor prognostic predictor in PM/DM patients [23]. It could be explained by that higher total GGO score and KL-6 level both indicated a more rapid progression of ILD and wider extent of lung involvement, resulting in respiratory failure in the early stage.

The value of CRP in predicting death in anti-MDA5 positive patients was rarely reported before. CRP is a general reflection of inflammatory which has been widely tested clinically. In a large multicenter myositis-associated ILD cohort, CRP > 10 mg/L was revealed as an independent poor prognostic risk factor [11]. Moreover, a meta-analysis indicated that higher CRP level is associated with an increased risk of developing ILD in PM/DM patients [24]. Consistent with these findings, our study demonstrated higher initial CRP levels significantly associated with both RPILD and poor outcome in anti-MDA5 positive patients.

Different from previous studies, we didn't find any association between CADM and poor prognosis in our study. This discrepancy was caused by the strong connection between CADM and anti-MDA5 antibody in the cohorts including all types of myositis, which apparently doesn't exist in our cohort. Although initial serum ferritin wasn't identified as an independent predictor for death, it was still significantly associated RPILD. In addition, shorter disease duration was also revealed as a predictor for developing RPILD in this study. Thirty-one patients had RPILD at their first hospitalization, and only four patients developed RPILD during follow-up, which suggests that the rapid progression of ILD mostly happens in the early stage of the disease.

More than half of the patients were treated with initial combination regimens, and it turned out the initial combination treatment significantly improve the prognosis, which was in accordance with a prospective
study [7]. Owing to its nature of retrospective study, treatment regimens relied on attending physician’s decision, instead of a pre-determined protocol. Some of the patients with diffuse GGO on HRCT, which was difficult to be distinguished from infections, were treated with step-up regimens due to the concern of severe infections. This may lead to exaggeration of the advantages of initial combined treatment. Initial treatment regimens were not included into the risk factor analysis for RPILD owing to the majority of RPILD cases occurred before therapy were initiated. Although IVIG was reported effective in treating PM/DM associated ILD [25], such efficacy was not observed in our study.

There are several limitations of this study. First, patients were all recruited from a single center of a tertiary hospital which may lead to a bias of a more severe form of this disease. Second, pulmonary function test, which has been reported as a potential prognostic factor, was not included into analysis, since many patients suffered a severe chest congestion and were unable to complete the lung function tests.

Conclusions

In conclusion, we observed that anti-MDA5 positive patients presented a high prevalence of ILD on admission, resulting in a high short-term mortality rate. Higher total GGO score, higher levels of initial KL-6 and CRP were identified as poor prognostic factors in anti-MDA5 positive patients, however initial intensive treatment may improve the prognosis.

Abbreviations

ANA, anti-nuclear antibody; anti-MDA5, anti-melanoma differentiation-associated protein-5; CADM, clinically amyopathic dermatomyositis; CK, creatine kinase; CNI, calcineurin inhibitors; CRP, C-reactive protein; CYC, cyclophosphamide; DM, dermatomyositis; ESR, erythrocyte sedimentation rate; GGO, ground-glass opacity; HR, hazard ratio; HRCT, high-resolution CT; ILD, interstitial lung disease; IQR, interquartile range; IVIG, intravenous immunoglobulin; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; PaO2, peripheral capillary oxygen saturation; PM, polymyositis; RPILD, rapidly progressive interstitial lung disease; SD, standard deviation

Declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2020-KY-194).

Consent for publication

Not applicable.
Availability of data and materials

Data can be requested from the corresponding author.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the National Natural Science Foundation of China (grant number U1704177, U1904164).

Authors' contributions

YQ, LS, and YZ designed the study. YQ, ZX and LK collected the data. WS and CY scored all radiographs. LK analyzed the data. YQ and LT interpreted the data. YQ, LT, and LK wrote the manuscript. All authors reviewed and approved the manuscript.

Acknowledgements

Not applicable.

References

1. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, cadm-140, in japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.

2. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of japanese patients with dm. Rheumatology. 2012;51:1278–84.

3. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013;65:1316–24.

4. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. Rna helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–200.

5. Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology. 2018;57:2114–9.
6. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68:689–94.

7. Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. ARTHRITIS RHEUMATOL. 2020;72:488–98.

8. Matsuda KM, Yoshizaki A, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J DERMATOL. 2020;47:483–9.

9. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1713–9.

10. Ishigaki K, Maruyama J, Hagino N, Murota A, Takizawa Y, Nakashima R, et al. Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis. RHEUMATOL INT. 2013;33:2381–9.

11. Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology. 2018;57:1212–21.

12. Gono T, Kuwana M. Inflammatory myopathies: choosing the right biomarkers to predict Ild in myositis. NAT REV RHEUMATOL. 2016;12:504–6.

13. Ye Y, Fu Q, Wang R, Guo Q, Bao C. Serum kl-6 level is a prognostic marker in patients with anti-mda5 antibody-positive dermatomyositis associated with interstitial lung disease. J CLIN LAB ANAL. 2019;33:e22978.

14. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.

15. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7.

16. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J AM ACAD DERMATOL. 2002;46:626–36.

17. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section ct obtained at 10-mm increments versus limited three-level thin-section ct for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977–83.
18. Zweig MH, Campbell G. Receiver-operating characteristic (roc) plots: a fundamental evaluation tool in clinical medicine. CLIN CHEM. 1993;39:561–77.

19. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J RHEUMATOL. 2001;28:2230–7.

20. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-mdx antibodies in european patients with polymyositis/dermatomyositis. CLIN EXP RHEUMATOL. 2014;32:891–7.

21. Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ARTHRITIS RES THER. 2018;20:7.

22. Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-mdax antibody-positive dermatomyositis patients. MOD RHEUMATOL. 2018;28:133–40.

23. Arai S, Kurasawa K, Maezawa R, Owada T, Okada H, Fukuda T. Marked increase in serum kl-6 and surfactant protein d levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. MOD RHEUMATOL. 2013;23:872–83.

24. Zhang L, Wu G, Gao D, Liu G, Pan L, Ni L, et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLOS ONE. 2016;11:e155381.

25. Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. LUNG. 2009;187:201–6.

Figures
Figure 1

Survival curves of anti-MDA5 positive patients in each group based on initial KL-6, CRP level, total GGO score and initial combined treatment.